Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05574296 · ClinicalTrials.gov registry record · Phase 1
Hydrogen's Feasibility and Safety as a Therapy in ECPR
A Phase 1 study of Cardiac Arrest and Extracorporeal Membrane Oxygenation, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 4
- Study locations
NCT05574296: Recruiting Phase 1 study of Cardiac Arrest and Extracorporeal Membrane Oxygenation, sponsored by Boston Children's Hospital.
NCT05574296 is a Phase 1 study of Cardiac Arrest and Extracorporeal Membrane Oxygenation that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 53 participants, below the 1,478-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05574296, a Phase 1 study of Cardiac Arrest and Extracorporeal Membrane Oxygenation, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.
Primary Outcome
Percentage of the first 72 consecutive post-arrest hours (starting at the time of first CPR initiation) in which H2 gas was administered via all of the applicable pathways (e.g. mechanical ventilator and ECMO membrane).
Conditions Studied
Interventions
- OTHER Usual care
- DRUG Hydrogen
Study Locations (4)
District of Columbia
- Children's National Hospital - Washington D.C.
Massachusetts
- Boston Children's Hospital - Boston
Missouri
- Children's Mercy Kansas City - Kansas City
Utah
- Primary Children's Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
What NCT05574296 shows while recruiting
NCT05574296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 1,478-participant average among 31 other Cardiac Arrest trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Cardiac Arrest appearing as the primary indexed condition, and to 2 interventions - of which Usual care is the first listed.
NCT05574296 reports a single indexed study location in District of Columbia, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT05574296 about?
NCT05574296 is a clinical study titled "Hydrogen's Feasibility and Safety as a Therapy in ECPR". The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients ...
What is the current status of trial NCT05574296?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2024-03-04. Estimated completion is 2027-08-31.
What conditions does trial NCT05574296 study?
This clinical trial studies the following conditions: Cardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion Injury.
What interventions are being tested in trial NCT05574296?
The interventions under investigation include: Usual care (OTHER), Hydrogen (DRUG).
Who is sponsoring clinical trial NCT05574296?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05574296 being conducted?
This trial has 4 study locations across District of Columbia, Massachusetts, Missouri, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Arrest
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05574296's enrollment target sits among peer trials
53 19th of 31 higher than 13 of 31 other Cardiac Arrest trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Arrest trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-CA Neuroprotection With Magnesium
RECRUITING · Phase 1
-
Packed Red Blood Cell Transfusion During Cardiac Arrest
RECRUITING · Phase 1
-
Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
COMPLETED · Phase 1
-
Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest
COMPLETED · Phase 1
-
Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation
COMPLETED · Phase 1
-
Reoxygenation After Cardiac Arrest II (REOX II Study)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI